多巴胺激动剂治疗泌乳素瘤：它们仍是首选吗？
Dopamine agonists in the treatment of prolactinoma: are they still first choice?
机构信息
Reproductive Endocrine Group at Fertility Associates, Auckland, New Zealand.
出版信息
Intern Med J. 2011 Feb;41(2):156-61. doi: 10.1111/j.1445-5994.2010.02410.x.
Dopamine agonist therapy has been the cornerstone treatment for prolactinoma since the 1970s, replacing surgery in the primary management of this condition. These agents are effective in the management of prolactin excess, have a low side-effect profile, and in some cases may even be curative. However, recent studies of high dose dopamine agonists used in Parkinson's disease have raised the possibility that these drugs may be associated with cardiac valvulopathy. This paper discusses the modern use of dopamine agonists in a patient with prolactinoma.
多巴胺激动剂治疗自 20 世纪 70 年代以来一直是催乳素瘤的基石治疗方法，取代了手术在这种情况下的主要治疗。这些药物在管理催乳素过多方面有效，副作用低，在某些情况下甚至可能是治愈性的。然而，最近对帕金森病中使用高剂量多巴胺激动剂的研究提出了这些药物可能与心脏瓣膜病有关的可能性。本文讨论了催乳素瘤患者中多巴胺激动剂的现代应用。
Zotero 插件